AVACLYR Drug Patent Profile
✉ Email this page to a colleague
When do Avaclyr patents expire, and when can generic versions of Avaclyr launch?
Avaclyr is a drug marketed by Fera Pharms Llc and is included in one NDA.
The generic ingredient in AVACLYR is acyclovir. There are fifty-six drug master file entries for this compound. Seventy suppliers are listed for this compound. Additional details are available on the acyclovir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Avaclyr
A generic version of AVACLYR was approved as acyclovir by TEVA on April 22nd, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AVACLYR?
- What are the global sales for AVACLYR?
- What is Average Wholesale Price for AVACLYR?
Summary for AVACLYR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 184 |
| Patent Applications: | 531 |
| DailyMed Link: | AVACLYR at DailyMed |
US Patents and Regulatory Information for AVACLYR
AVACLYR is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting AVACLYR
INDICATED FOR THE TREATMENT OF ACUTE HERPETIC KERATITIS (DENDRITIC ULCERS) IN PATIENTS WITH HERPES SIMPLEX (HSV-1 AND HSV-2) VIRUS
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fera Pharms Llc | AVACLYR | acyclovir | OINTMENT;OPHTHALMIC | 202408-001 | Mar 29, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
